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Abstract
Background: There is no randomized clinical trials with recurrence of atherosclerotic cardiovascular disease
(ASCVD) as a major outcome with rosuvastatin. In order to analyze potential differences in the clinical response to
atorvastatin and rosuvastatin in secondary ASCVD prevention, we have analyzed the clinical evolution of those
subjects of the Dyslipemia Registry of the Spanish Society of Arteriosclerosis (SEA) who at the time of inclusion in
the Registry had already suffered an ASCVD.
Methods: This observational, retrospective, multicenter, national study was designed to determine potential
differences between the use of atorvastatin and rosuvastatin in the ASCVD recurrence. Three different follow-up
start-times were performed: time of inclusion in the registry; time of first event if this occurred after 2005, and time
of first event without date restriction.
Results: Baseline characteristics were similar between treatment groups. Among atorvastatin or rosuvastatin users,
89 recurrences of ASCVD were recorded (21.9%), of which 85.4% were coronary. At the inclusion of the subject in
the registry, 345 participants had not suffered a recurrence yet. These 345 subjects accumulated 1050 person-years
in a mean follow-up of 3 years. Event rates were 2.73 (95% CI: 1.63, 4.25) cases/100 person-years and 2.34 (95% CI:
1.17, 4.10) cases/100 person-years in the atorvastatin and rosuvastatin groups, respectively. There were no
statistically significant differences between the two groups independently of the follow-up start-time.
Conclusions: This study does not find differences between high doses of rosuvastatin and atorvastatin in the
recurrence of ASCVD, and supports their use as clinically equivalent in secondary prevention of ASCVD.
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Background
Reduction of cholesterol transported in low-density lipo-
proteins (LDLc) is one of the mainstays of atheroscler-
otic cardiovascular disease (ASCVD) prevention, since
multiple studies have demonstrated the causal role of
LDLc in the pathogenesis of atherosclerosis, and the
benefit of LDLc reduction in blood [1].
One central idea in ASCVD prevention is that the type
and intensity of any preventive measure should be
conditioned by the risk of developing ASCVD over time,
especially in the short and medium term [2]. For LDLc
reduction, the main international scientific societies rec-
ommend undertaking hygienic-dietary measures as the
first step of lipid-lowering treatment in all patients, but
also concomitantly initiating hypolipidemic treatment
with potent statins in high-risk groups: subjects with
very high concentrations of LDLc, subjects affected by
severe genetic form of hypercholesterolemia, and pa-
tients who have already suffered an ASCVD event [3, 4].
In all of these cases, these guidelines recommend aiming
to LDLc reduction > 50% with the use of high potency
statins at high doses. The American College of Cardi-
ology/American Heart Association guideline on the
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treatment of blood cholesterol to reduce ASCVD risk in
adults, after analyzing the hypolipidemic efficacy of dif-
ferent statins in multiple clinical trials and performing
head-to-head comparison among statins, classify them
according to their hypolipidemic effect in statins of low,
medium, and high potency. The latter group encom-
passes rosuvastatin at doses of 20 mg/day and 40mg/
day, and atorvastatin at doses of 40 mg/day and 80 mg/
day. High potency statins allow LDLc reduction > 50%
and for that intensity, a similar clinical benefit is as-
sumed [3].
However, there are few observational reports and no
randomized clinical trials in secondary prevention with re-
currence of ASCVD as a major outcome with rosuvastatin,
in contrast to atorvastatin [5–8]. So, the assumption of
equivalent clinical benefit is based on their lipid-lowering
capacity and the clinical benefit of rosuvastatin demon-
strated in subjects in primary prevention. Given that sub-
jects in secondary prevention have different clinical
characteristics, such as the currently high prevalences of
diabetes [9] and vascular revascularization [10] among
them, and different concomitant medications, from sub-
jects in primary prevention, it would be good to know
whether the benefit of both statins is similar in secondary
prevention in real life.
In order to analyze potential differences in the clinical
response to atorvastatin and rosuvastatin in subjects in
secondary ASCVD prevention, we have analyzed the
clinical evolution of those subjects of the Dyslipemia
Registry of the Spanish Society of Arteriosclerosis (SEA)
who at the time of inclusion in the Registry had already
suffered an ASCVD.
Material and methods
This observational, retrospective, multicenter, national
study in Spain was designed to determine potential dif-
ferences between the use of atorvastatin and rosuvastatin
in the ASCVD recurrence. The information was ob-
tained from the Dyslipidemia Registry of the SEA [11].
This is an active online registry, where 50 certified lipid
clinics distributed throughout all regions of Spain report
cases of various types of primary hyperlipidemias. An-
onymous clinical data collection in this registry was ap-
proved by a central ethical committee (Comité Ético de
Investigación Clínica de Aragón, CEICA) and partici-
pants gave their written informed consent. Inclusion cri-
teria were standardized in 5 training sessions before case
recruitment. For patients in secondary prevention, the
registry collects personal and family health history, an-
thropometry, physical examination, laboratory data, type
of ASCVD, age at which the ASCVD event occurred, age
at which statin treatment began, and history of lipid-
lowering treatment [12]. Patients were eligible for inclu-
sion in this study if they were 18 years of age or older
with previous ASCVD at inclusion in the registry.
ASCVD was defined as: coronary (myocardial infarction,
coronary revascularization procedure, sudden death);
cerebral (ischemic stroke with > 24-h neurological deficit
without evidence of bleeding in brain imaging tests);
peripheral vascular disease (PAD) (intermittent claudica-
tion with ankle arm index< 0.9, or arterial revasculariza-
tion of lower limbs) or symptomatic or asymptomatic
abdominal aortic aneurysm. Arterial hypertension was
defined as systolic blood pressure ≥ 140mmHg or dia-
stolic blood pressure ≥ 90 mmHg or self-reported use of
antihypertensive medication. Diabetes was defined as
fasting plasma glucose ≥126 mg/dl, HbA1c ≥6.5%, or
self-reported treatment with antidiabetic medications.
Current smoking was defined as current smoking or
having smoked in the last year. Former smoker was de-
fined as a subject having smoked at least 50 cigarettes in
his lifetime, but not having smoked in the last year.
Follow up
The registry is designed so that at least once a year the data
on the clinical evolution of the included patients are updated,
with new anthropometric data, changes in risk factors or
medication, and the appearance of new ASCVD events.
The main endpoint was defined as the occurrence of a
new major ASCVD event composed of coronary heart dis-
ease (coronary death, acute coronary syndrome requiring
hospitalization, or coronary revascularization due to an-
gina), cerebrovascular (fatal and non-fatal stroke, or ca-
rotid revascularization), and peripheral arterial disease
(arterial revascularization of the lower extremities).
Participants were divided according to the type of statins
recorded at the time of inclusion in the registry. The statin
documented in the registry represented the treatment for
the follow-up years prior to the recurrence or censoring.
Recurrent ASCVD event dates were collected and, in their
absence, participants were censored at the date the follow-
up data was obtained from the registry. Three different
follow-up start-times were performed: starting from the
time of inclusion in the registry (all participants had a pre-
vious event), starting from the time of first event if this oc-
curred after 2005, and starting from the time of first event
without date restriction.
Statistical analysis
Data are expressed as mean and standard deviation for
continuous variables with normal distribution and they
were analyzed with the Student’s t test. Categorical vari-
ables are expressed as a percentage and analyzed by the
× 2 test. The rates of adverse events up to the end of the
follow-up were calculated by considering observed
person-time and survival curves were created by Kaplan-
Meier estimation, and the groups were compared by log
rank test. The association between type of statin and
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ASCVD events was calculated using Poisson regression.
Multivariable Poisson regression models were fitted in-
cluding the covariates: age and sex (model 1), diabetes,
hypertension, smoking status, body mass index (BMI),
non-high-density lipoprotein (non-HDL) cholesterol,
HDL cholesterol and ezetimibe use.
We conducted this study in accordance with the Dec-
laration of Helsinki for the protection of the rights and
welfare of people participating in biomedical research.
Results
Patient characteristics
In the registry, 985 subjects had had an ASCVD event at
the time of their inclusion. On March 31st, 2019, follow-
up data were evaluated and 475 subjects were excluded
due to incomplete data, changes in the lipid-lowering
drugs, follow-up less than 1 year, or loss to follow-up.
There were no relevant clinical differences at registry be-
tween those included and excluded for the analysis
(Additional file 3: Table S1). Only those subjects under
continuous treatment with atorvastatin (n = 243) or
rosuvastatin (n = 164) were included in this analysis
(Fig. 1). Clinical characteristics at the moment of inclu-
sion in the registry only differed in the gender propor-
tion between both treatment groups (Table 1). In the
atorvastatin group men were more frequent. At inclu-
sion, the mean age in both groups was 61 years, there
were no differences in body mass index, the prevalence
of hypertension, diabetes, or smoking history between
those patients on atorvastatin and rosuvastatin. The age
of the first ASCVD and the type of ASCVD were also
similar between the groups (Table 1).
Total cholesterol and non-HDLc were higher before
treatment in those subjects to whom rosuvastatin was
prescribed. After treatment, HDLc has higher in the
rosuvastatin group, and the differences in total choles-
terol and non-HDLc were reduced to a level at which
they did not reach statistical significance any more
(Table 1). The mean dose of atorvastatin and rosuvasta-
tin were 50.8 (24.7) mg/day and 21.4 (9.6) mg/day, re-
spectively, corresponding to a medium dose of a high
potency statin and they were equivalent with respect to
their lipid-lowering efficacy. At the highest doses mar-
keted in Spain (rosuvastatin 20 mg and atorvastatin 80
mg), there were no significant differences in the reduc-
tion of LDLc. The concomitant use of ezetimibe was
very high among patients on atorvastatin, but higher in
those patients on rosuvastatin, 57.9 and 69.5%, respect-
ively (p = 0.023) (Table 1).
Recurrences
In the registry, among atorvastatin and rosuvastatin users,
89 recurrences of ASCVD after a first event were recorded
(21.9%), of which 85.4% were coronary, 11.2% ischemic
stroke, and 3.4% PAD; there were no hemorrhagic strokes
or abdominal aortic aneurism surgery during evolution. At
the inclusion of the subject in the registry, 345 participants
had not suffered a recurrence yet. Thus 62 recurrences
Fig. 1 Recruitment process
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occurred before and 27 after inclusion on the registry.
These 345 subjects accumulated 1050 person-years in a mean
follow-up of 3 years. Event rates were 2.73 (95% CI: 1.63,
4.25) cases/100 person-years and 2.34 (95% CI: 1.17, 4.10)
cases/100 person-years in the atorvastatin and rosuvastatin
groups respectively (Fig. 2). There were no statistically signifi-
cant differences between the two groups (crude, adjusted for
age and sex, and for major cardiovascular risk factors Poisson
models as described in methods). Subjects with recurrent
ASCVD presented higher pre-treatment concentration of
non-HDLc than those subjects without recurrences during
the follow-up. All other clinical and biochemical variables did
not differ between those who suffered recurrence and those
who did not (Additional file 4: Table S2).
Among the patients in the registry with ASCVD (n =
407), 287 had their first episode in the last 15 years (year
2004 or later). Among them, 176 took atorvastatin at the
time of inclusion in the registry and 111 subjects rosu-
vastatin. The Kaplan–Meier survival estimates for the
end-point from the moment of the first event are shown
in Additional file 1: Figure S1. Within an average follow-
up of 7.5 years, 47 (16.4%) patients (28 in the atorva-
statin group and 19 in the rosuvastatin group) suffered a
second episode of ASCVD. Crude rates for this follow-
up of 2154 person-years were 2.2 (95% CI 1.5, 3.1) and
2.2 (95% CI 1.3, 3.3) episodes per 100 person-years for
the atorvastatin and rosuvastatin groups respectively,
without finding statistically significant differences between
the two groups (crude models, adjusted for age and sex,
and for major cardiovascular risk factors as described in
methods). Results did not differ when subjects with first
events prior to 2004 (10.8 years mean follow-up) were in-
cluded in the model (Additional file 2: Figure S2).
Discussion
The present work shows that the recurrence of ASCVD
events in the Registry of Dyslipemias of the SEA does
not reveal relevant differences between those subjects in
Table 1 Clinical characteristic of subjects with CVD at inclusion in the Registry according to statin prescribed, and lipid values at
diagnosis of dyslipidemia in the Lipid Clinic without lipid-lowering treatment and after lipid-lowering treatment recorded at
inclusion in the Registry
Variables Atorvastatin (n = 243) Rosuvastatin (n = 164) P
Gender (Male), % (n) 78.2 [190] 68.9 [113] 0.046
Age at inclusion, years 60.9 (11.1) 60.6 (9.9) 0.743
Body mass index, (Kg/m2) 28.9 (4.1) 28.6 (4.3) 0.595
ASCVD type (CHD/Stroke/PAD), % 77.3/14.5/7.0 79.3/12.2/5.5 0.460
Age first ASCVD event 51.7 (11.4) 51.1 (10.5) 0.561
Tobacco consumption, % (n) 18.9 [45] 15.5 [25] 0.461
Hypertension, % (n) 48.6 [118] 56.1 [92] 0.164
Diabetes, % (n) 30.9 [75] 31.7 [52] 0.943
Glucose, mg/dL 113.6 (33.5) 108.4 (32.4) 0.130
Age statin onset 48.4 (12.3) 49.4 (11.2) 0.477
Total cholesterol, mg/dl
Pre-treatment 296.8 (102.6) 322.1 (111.1) 0.020
Post-treatment 172.9 (55.6) 182.6 (49.8) 0.065
HDL cholesterol, mg/dl
Pre-treatment 45.2 (14.3) 46.6 (12.8) 0.285
Post-treatment 47.1 (13.8) 49.6 (11.6) 0.048
Non-HDL cholesterol, mg/dl
Pre-treatment 251.6 (100.8) 275.5 (109.9) 0.027
Post-treatment 110.6 (39.9) 119.0 (49.5) 0.072
Triglycerides, mg/dl
Pre-treatment 241.5 (291.3) 209.2 (229.4) 0.213
Post-treatment 161.5 (175.2) 160.2 (153.8) 0.938
Statin daily dose, mg/day 50.8 (24.7) 21.4 (9.6) –
Ezetimibe use, % (n) 57.9 [140] 69.5 [114] 0.023
Values are percentage [count], mean (SD), as applicable. ASCVD Denotes arteriosclerotic cardiovascular disease, CHD Coronary heart disease, PAD Peripheral artery
disease, HDL High-density lipoprotein
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treatment with rosuvastatin or atorvastatin at the begin-
ning of the follow-up. These results support the recom-
mendation to use them as clinically equivalent in the
secondary prevention of ASCVD when used at appropri-
ate dose.
There are very limited studies that have analyzed the
differences in clinical ASCVD events between statins.
The Pravastatin or Atorvastatin Evaluation and Infection
Trial (PROVE IT) analyzed the efficacy of atorvastatin
80 mg/day and pravastatin 40 mg/day in the prevention
of cardiovascular recurrence after acute coronary syn-
drome. Atorvastatin provided greater protection against
death or major cardiovascular events than pravastatin
did. However, they used different doses, not equivalent
with respect to their lipid-lowering potency, so their re-
sults support the use of powerful statins at high doses
compared to statins of intermediate potency [12]. The
Treating to New Targets (TNT) demonstrated that in-
tensive lipid-lowering therapy with 80mg of atorvastatin
per day in patients with stable coronary disease provides
benefit when compared with 10 mg of atorvastatin per
day. Again, they used different doses, although with
identical conclusions [5]. The IDEAL study, enrolled pa-
tients with a history of acute MI and were randomly
assigned to receive a high dose of atorvastatin (80 mg/
day) or simvastatin (20 mg/day). The intensive lowering
of LDLc did not result in a significant reduction in the
primary outcome of major coronary events, but did re-
duce the risk of other composite secondary end points
and nonfatal acute MI [6]. Hence, there is high quality
evidence that intensive lipid-lowering treatment with
further reductions in LDLc produce further reductions
in ASCVD [13], but there is no evidence of clinically
meaningful differences between statins with the same
lipid-lowering potency. In this study, we show that when
using similarly powered statins in a high-risk population,
rates of second events are similar, no matter the statin
used.
An added value to our data is the high use of com-
bined treatment in our registry. It must be kept in mind
that these are specialized units and that many patients in
the registry have severe primary dyslipidemias, many of
them familial hypercholesterolemia. The fact that the re-
sults are similar in those subjects after adjusting for eze-
timibe in the treatment gives more information about
the clinical equivalence of both statins at equipotent
doses.
Our study has several limitations. The main one is that
it is an observational study and therefore subject to
biases in the use of one or another statin. However, the
data have been adjusted with the different potentially
confounding variables without modifying the results.
The follow-up of the subjects is also variable and it is
not possible to analyze the therapeutic compliance dur-
ing the follow-up. However, no differences in compli-
ance between drugs have been described, so it does not
seem to be a major problem. Finally, changes in treat-
ment have not been covered during the period of follow-
up previous to inclusion in the registry and some
subjects have been able to change from atorvastatin to
rosuvastatin and vice versa. This extreme is exceptional
in the registry since the usual is the addition of ezeti-
mibe in case of not achieving therapeutic goals, and the
use of ezetimibe in both groups is well balanced [14].
Fig. 2 Cumulative incidence of the composite primary end point after inclusion in the registry
Perez-Calahorra et al. Lipids in Health and Disease          (2019) 18:216 Page 5 of 6
Conclusion
This observational and retrospective analysis of ASCVD
recurrences does not find appreciable clinical differences
between high doses of rosuvastatin and atorvastatin, and
supports their use as clinically equivalent in secondary
prevention of ASCVD.
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1186/s12944-019-1153-x.
Additional file 1: Figure S1 Cumulative incidence of the composite
primary end point in those 287 subjects with a first episode in the last
15 years (year 2004 or later).
Additional file 2: Figure S2 Cumulative incidence of the composite
primary end point in all subjects with a first ASCVD included in the
Registry
Additional file 3: Table S1 Clinical and biochemical differences at
Registry between subjects with and without ASCVD recurrence after
inclusion in the Registry
Additional file 4: Table S2 Characteristics of patients with ASCVD at
inclusion in the Registry according to inclusion or exclusion in the follow-
up.
Acknowledgements
Not applicable.
Authors’ contributions
All authors contributed to the study conception and design. Material
preparation, data collection and analysis were performed by all authors. The
first draft of the manuscript was written by FC and ML, and all authors
commented on previous versions of the manuscript. All authors read and
approved the final manuscript.
Funding
This study was funded by CIBERCV (grant number CB16/11/00451), and
Sociedad Española de Arteriosclerosis (SEA 2019).
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
Anonymous clinical data collection in this registry was approved by a central
ethical committee (Comité Ético de Investigación Clínica de Aragón, CEICA)
and participants gave their written informed consent. All procedures
performed in studies involving human participants were in accordance with
the ethical standards of the institutional and/or national research committee
and with the 1964 Helsinki declaration and its later amendments or
comparable ethical standards.
Consent for publication
Not applicable.
Competing interests
Fernando Civeira has received a speaker honorarium from Ferrer. The other
authors declare that they have no conflict of interest.
Author details
1Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, CIBERCV,
Zaragoza, Spain. 2Lipid and Vascular Risk Unit. Internal Medicine Service,
CIBEROBN, Hospital de Bellvitge, Hospitalet de Llobregat, Spain. 3Lipid Unit,
Endocrinology Department, Hospital Universitario Insular de Gran Canaria,
Instituto Universitario de Investigaciones Biomédicas y Sanitarias, Universidad
de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain. 4Unitat
de Medicina Vascular i Metabolism, Hospital Universitari Sant Joan, Institut
d’Investigació Sanitària Pere Virgili (IISPV), CIBERDEM, Reus, Tarragona, Spain.
5Lipid Unit, Endocrinology and Nutrition Service, Institut d’Investigacions
Biomèdiques August Pi Sunyer, CIBEROBN, Hospital Clínic, Barcelona, Spain.
6Lipid Unit, Instituto Maimónides de Investigación Biomédica de Córdoba
(IMIBIC), CIBEROBN, Universidad de Córdoba, Hospital Universitario Reina
Sofía, Córdoba, Spain. 7Universidad de Zaragoza, Zaragoza, Spain.
Received: 27 July 2019 Accepted: 26 November 2019
References
1. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al.
Low density lipoproteins cause atherosclerotic cardiovascular disease. 1.
Evidence from genetic, epidemiologic, and clinical studies. A consensus
statement from the European Atherosclerosis Society Consensus Panel. Eur
Heart J. 2017;38:2459–72.
2. Domanski M, Lloyd-Jones D, Fuster V, Grundy S. Can we dramatically reduce
the incidence of coronary heart disease? Nat Rev Cardiol. 2011;8:721–5.
3. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013
ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic
cardiovascular risk in adults. J Am Coll Cardiol. 2014;63(25pt. B):2889–934.
4. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, ESC
Scientific Document Group, et al. 2016 European Guidelines on
cardiovascular disease prevention in clinical practice: The Sixth Joint Task
Force of the European Society of Cardiology and Other Societies on
Cardiovascular Disease Prevention in Clinical Practice (constituted by
representatives of 10 societies and by invited experts) Developed with the
special contribution of the European Association for Cardiovascular
Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–21.
5. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al.
Intensive lipid lowering with atorvastatin in patients with stable coronary
disease. N Engl J Med. 2005;352:1425–35.
6. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I,
et al. High-dose atorvastatin vs usual dose simvastatin for secondary
prevention after myocardial infarction: the IDEAL study: a randomized
controlled trial. JAMA. 2005;294:2437–45.
7. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al.
Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering
(MIRACL) Study Investigators. Effects of atorvastatin on early recurrent
ischemic events in acute coronary syndromes: the MIRACL study: a
randomized controlled trial. JAMA. 2001;285:1711–8.
8. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M,
Rudolph AE, et al. Stroke Prevention by Aggressive Reduction in Cholesterol
Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or
transient ischemic attack. N Engl J Med. 2006;355:549–59.
9. Kim SH, Chunawala L, Linde R, Reaven GM. Comparison of the 1997 and
2003 American Diabetes Association classification of impaired fasting
glucose: impact on prevalence of impaired fasting glucose, coronary heart
disease risk factors, and coronary heart disease in a community-based
medical practice. J Am Coll Cardiol. 2006;48:293–7.
10. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, ODYSSEY OUTCOMES
Committees and Investigators, et al. Alirocumab and Cardiovascular Outcomes after
Acute Coronary Syndrome. N Engl J Med. 2018;379:2097–107.
11. Perez-Calahorra S, Laclaustra M, Marco-Benedí V, Lamiquiz-Moneo I, Pedro-
Botet J, Plana N, et al. Dyslipemia Registry of Spanish Arteriosclerosis Society.
Effect of lipid-lowering treatment in cardiovascular disease prevalence in
familial hypercholesterolemia. Atherosclerosis. 2019;284:245–52.
12. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al.
Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in
Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering
with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.
13. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L,
Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more
intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000
participants in 26 randomised trials. Lancet. 2010;376:1670–81.
14. Pérez-Calahorra S, Sánchez-Hernández RM, Plana N, Valdivielso P, Civeira F.
National Dyslipidemia Registry of the Spanish Arteriosclerosis Society:
Current status. Clin Investig Arterioscler. 2017;29:248–53.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Perez-Calahorra et al. Lipids in Health and Disease          (2019) 18:216 Page 6 of 6
